Stephen F. Mahoney

Autre

US·SEC (Form 4)

Magenta Therapeutics, Inc.Viridian Therapeutics, Inc.\DE

Cumul. flow

Total declarations

Companies

▲ Purchases (1 ops.)

€447k

▼ Sales (1 ops.)

€33k

Latest filing published 09 Mar 2026 for Viridian Therapeutics, Inc.\DE, €191k. Read the official filing

Filing timeline

BuySale

Stephen F. Mahoney

Insider track record

Disclosed buys

Disclosed sells

Signal history

Closed purchases

Market purchases

Not enough history yet: 1 closed purchase, at least 2 are needed.

Purchases by company

Viridian Therapeutics, Inc.\DE 1 purchase · last 30 Sept 2024

Since each purchase

Viridian Therapeutics, Inc.\DE
Filed 30 Sept 2024 · 748 days ago · €447k
-9.9%
Entry US$23.61 · Close at T+365 US$21.27

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Stephen F. Mahoney: trading record in brief

This profile gathers the share dealings of Stephen F. Mahoney across 2 companies, led by Dianthus Therapeutics, Inc. /DE/ and Viridian Therapeutics, Inc.\DE. Over a trading history stretching from 14 September 2021 to 3 March 2026, the count stands at 6 filings.

Market trades split into 1 purchase (€447k) and 1 sale (€33k). On balance, insiders were net buyers of €414k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 3 share grants and 1 option exercise.

The newest entry dates from 9 March 2026: a share grant of €191k, in Viridian Therapeutics, Inc.\DE. The latest purchase dates back some time: it was published 748 days ago, on 30 September 2024. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.